Syngene International Limited has appointed Peter Bains as Managing Director & Chief Executive Officer of the company effective April 1, 2025.

Bains, 67 years, holds a bachelor’s degree in Science (Combined honours in Zoology and Physiology) from University of Sheffield, United Kingdom. He has global experience in strategic and operational leadership including at Board, CEO, and Senior Corporate levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years. Bains brings in differentiating characteristics with extensive experience in Biopharmaceuticals across business and technology segmentation (Biotech, Vaccines, Branded Generics, Life Sciences, and CRO) and geography encompassing both developed and emerging markets.

Bains had served as the Chief Executive Officer (CEO) and Member of the Board of Syngene International Limited for nearly six years, starting in 2010. During his tenure, he successfully led the company to its public listing in 2015. He joined the Biocon Group as an Independent Director in Biocon Limited in December 2022 and later was appointed as the Group CEO in September 2023. He also held the position of CEO at Sosei Group, a publicly traded biopharmaceutical company in Japan.

Prior to these roles, Bains had a distinguished 23-year career at GlaxoSmithKline (GSK), where he held several senior positions, including Head of Global Marketing and Senior Vice President of Commercial Development for GSK’s International region.